Soft‐tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies,
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …

Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur
almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location …

Highlights•This Clinical Practice Guideline provides key recommendations on the
management of soft tissue and visceral sarcomas.•Recommendations have been agreed …

Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular
subsets, characterised by a low to very low incidence in all populations. The majority of …

Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in
advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare …

Purpose This multicenter study, to our knowledge, is the first phase III trial to compare
trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma …

Background Previous trials from our group suggested an overall survival benefit with five
cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue …

PURPOSE To determine whether the administration of histology-tailored neoadjuvant
chemotherapy (HT) was superior to the administration of standard anthracycline plus …

Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis …